| pubmed-article:9239584 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C0002903 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C0015131 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C0022614 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C0143993 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C1444748 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C1705994 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C2348609 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:9239584 | lifeskim:mentions | umls-concept:C1513492 | lld:lifeskim |
| pubmed-article:9239584 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9239584 | pubmed:dateCreated | 1997-9-26 | lld:pubmed |
| pubmed-article:9239584 | pubmed:abstractText | Intraoperative monitoring of myogenic transcranial motor evoked responses (tc-MERs) requires an anesthetic technique that minimally depresses response amplitudes. Acceptable results have been obtained during opioid/N2O anesthesia, provided that the concentration of N2O does not exceed 50%. However, this technique may necessitate supplementation with additional agents to achieve adequate depth of anesthesia. Etomidate and ketamine have been reported anecdotally or in nonsurgical situations to produce little tc-MER depression. We investigated the effects on tc-MER amplitude and latency of supplementation of a sufentanil/N2O anesthetic with etomidate or ketamine in patients undergoing spinal instrumentation. Anesthesia was induced with etomidate 0.3 mg/kg and sufentanil 1.5 mg/kg and maintained with sufentanil 0.5 mg/kg/h and N2O 50%. Muscle relaxation was kept at 25% of control. Paired transcranial electrical stimulation was performed. Each patient randomly received either ketamine (0.5 mg/kg) or etomidate (0.1 mg/kg) as a single bolus intravenously, during stable surgical conditions. Triplicate tc-MERs were recorded from the tibialis anterior muscles before and 2, 5, 10, and 15 min after drug administration. Administration of ketamine did not significantly change tc-MER amplitudes, whereas etomidate resulted in a transient amplitude depression to 72% of control (p < 0.05) at 2 min after injection. Latency remained unchanged with both drugs. In conclusion, the data suggest that both ketamine (0.5 mg/kg) and etomidate (0.1 mg/kg) can be used to supplement sufentanil/N2O anesthetic without disrupting tc-MER monitoring. | lld:pubmed |
| pubmed-article:9239584 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9239584 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9239584 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9239584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9239584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9239584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9239584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9239584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9239584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9239584 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9239584 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9239584 | pubmed:issn | 0898-4921 | lld:pubmed |
| pubmed-article:9239584 | pubmed:author | pubmed-author:DrummondJ CJC | lld:pubmed |
| pubmed-article:9239584 | pubmed:author | pubmed-author:KalkmanC JCJ | lld:pubmed |
| pubmed-article:9239584 | pubmed:author | pubmed-author:BeenH DHD | lld:pubmed |
| pubmed-article:9239584 | pubmed:author | pubmed-author:UbagsL HLH | lld:pubmed |
| pubmed-article:9239584 | pubmed:author | pubmed-author:PorsiusMM | lld:pubmed |
| pubmed-article:9239584 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9239584 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9239584 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9239584 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9239584 | pubmed:pagination | 228-33 | lld:pubmed |
| pubmed-article:9239584 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:meshHeading | pubmed-meshheading:9239584-... | lld:pubmed |
| pubmed-article:9239584 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9239584 | pubmed:articleTitle | The use of ketamine or etomidate to supplement sufentanil/N2O anesthesia does not disrupt monitoring of myogenic transcranial motor evoked responses. | lld:pubmed |
| pubmed-article:9239584 | pubmed:affiliation | Department of Anesthesiology, University of Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:9239584 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9239584 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9239584 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
